ETC
IPHA

Exchange Traded Concepts’s Innate Pharma IPHA Stock Holding History

Exchange Traded Concepts’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62,752
Closed -$112K – 1461
2025
Q1 		$112K Sell
62,752
-14,598
-19% -$28.5K ﹤0.01% 1120
2024
Q4 		$143K Hold
77,350
– – ﹤0.01% 1069
2024
Q3 		$177K Sell
77,350
-8,887
-10% -$19.6K ﹤0.01% 1000
2024
Q2 		$167K Sell
86,237
-26,833
-24% -$67.4K ﹤0.01% 894
2024
Q1 		$326K Buy
113,070
+66,182
+141% +$173K 0.01% 773
2023
Q4 		$131K Buy
46,888
+11,890
+34% +$29.5K ﹤0.01% 850
2023
Q3 		$88.5K Sell
34,998
-7,433
-18% -$21.8K ﹤0.01% 945
2023
Q2 		$133K Buy
+42,431
New +$130K ﹤0.01% 879

Other funds holding IPHA

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $8.31B AUM 21.94% 1-Year Est. Return

Exchange Traded Concepts's IPHA Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Innate Pharma (IPHA) in Q2 2025, closing a stake of 62,752 shares — an estimated $112K sold.

Exchange Traded Concepts first reported a position in IPHA in Q2 2023 and held it in 8 quarters. The position peaked at $326K in Q1 2024. 9 funds tracked by Wall St. Rank hold IPHA as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Innate Pharma position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 62,752 Innate Pharma shares in Q2 2025, an estimated $112K.
  • Exchange Traded Concepts first reported a position in Innate Pharma in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Innate Pharma position peaked at $326K in Q1 2024.
  • 9 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.